Conceptio › Archive › ClinicalTrials.gov
ClinicalTrials.govpublic full text

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma

National Cancer Institute (NCI) · 2021
ClinicalTrials.gov · Datasets · License: Public Domain · 2021
Open Source ↗
lymphomamonoclonal-antibody
lymphoma, non-hodgkin lymphoma, diffuse large b-cell lymphoma, burkitt lymphoma, monoclonal antibody, dose finding, interventional, phase1
This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Related documents

Record · ID 902095
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.